Modern guidelines improve late relapse rates, outcomes in testicular cancer

CHICAGO — Centralized treatment and adherence to modern guidelines may account for “relatively low” rates of late relapse and improved long-term outcomes after treatment for testicular cancer, according to a speaker at ASCO.
“Late relapses as a unique entity with a worse prognosis compared [with] earlier relapses have been described for decades. However, published data reports a wide range, both in the prevalence and for prognosis,” Torgrim Tandstad, MD, PhD, from St. Olav’s University Hospital, Trondheim, Norway, said in a presentation.
Many of the

CHICAGO — Centralized treatment and adherence to modern guidelines may account for “relatively low” rates of late relapse and improved long-term outcomes after treatment for testicular cancer, according to a speaker at ASCO.
“Late relapses as a unique entity with a worse prognosis compared [with] earlier relapses have been described for decades. However, published data reports a wide range, both in the prevalence and for prognosis,” Torgrim Tandstad, MD, PhD, from St. Olav’s University Hospital, Trondheim, Norway, said in a presentation.
Many of the